Imatinib is an inhibitor aimed at PDGFRβ tyrosine kinase receptors, and Marion T. Weigel and colleagues found that imatinib inhibits the growth and induces apoptosis of breast cancer cells [99]. The gene discussed is PDGFRB; the disease is breast carcinoma.